[
Home
]
[
Up
]
[
Store Home Page
]
[
Info
]
[
Search
]
[
View Basket
]
[
Checkout
]
[
Send email
]
[
Login
]
Items Ordered:
Cart Value:
New Products:
1.
Advances in Large Scale BioManufacturing and Scale-Up Production
2.
Monoclonal Antibodies Report Part I
3.
Spending on Telehealth Solutions in Europe 2007 to 2012 (Databook)
4.
Spending on Telehealth Solutions in North America through 2007 to 2012 (Databook)
5.
Irritable Bowel Syndrome Potentially profitable market is open for the taking
6.
Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications
7.
Hepatocellular Carcinoma Opportune indication for novel therapies
8.
Generic Series An Introduction to the Canadian Generics Market Key trends and leading companies shaping the market
9.
Female Sexual Dysfunction Results from Datamonitor's 2005 physician survey
10.
The Global Anti-Infectives Market Outlook to 2011
Best Sellers:
1.
Advances in Large Scale BioManufacturing and Scale-Up Production
2.
Vaccines - The World Market
3.
Legal aspects of outsourcing contracts in the pharmaceutical industry: A practical guide
4.
BioNewsCast Press Release Distribution Service
5.
Therapeutic Class Overviews
6.
4th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production
7.
The Cardiovascular Market Outlook to 2011
8.
Preparing Health Technology Submissions for Pharmaceutical Products
9.
Guide to US Reimbursement for Drugs, Medical Devices, and Diagnostics
10.
Computer-Assisted Drug Design Course
Biopharmaceuticals Current Market Dynamics & Future Outlook
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 130 such products are currently being marketed around the world including thirteen blockbuster drugs.
The global market for biopharmaceuticals, which is currently valued at US$48 billion, has been growing at an impressive compound annual growth rate of 19% over the previous five years.
With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of the decade.
This report reviews the current status of the market of biopharmaceuticals, highlights the differences between regional markets, maps leading biopharmaceutical classes and discusses the different windows of opportunities opening in this market including the potential for biogenerics.
The report provides figures of market size, growth rates and historical evolution of the global, North American, European and Japanese biopharmaceutical markets.
It also provides sales and growth rate figures for the following leading biopharmaceutical products with combined revenue of over US$38 billion: Epogen / Aranesp, Eprex / Procrit / Erypo, Remicade, Neupogen / Neulasta, MabThera / Rituxan, Avonex, Enbrel, Pegasys / Roferon A, Peg-Intron / Intron A, Betaferon / Betaseron, Humulin / Humalog, Rebif, Synagis and Herceptin.
Erythropoietins with a market size of over US$11 billion and rising, Monoclonal Antibodies with a market size approaching US$10.2 billion and a stratospheric growth rate, Human Insulin and analogs, Interferon and Colony Stimulating Factors are some of the main biopharmaceutical classes profiled in this report.
Each class profile contains a thoughtful market dynamics analysis including size, evolution, growth rate, leading participants' market shares and highlights of the strategic opportunities relating to that particular segment of the market.
The report also discusses the biopharmaceutical market outlook, growth potential, attractive areas of growth, technological innovations, products in development and biogenerics opportunities.
Written with the senior executive needs in mind, Biopharmaceuticals - Current Market Dynamics & Future outlook, is a must read for pharmaceutical and medical biotech professionals interested in high growth area therapeutics.
Report Code: ASI0505-5
Date Published: May 2005
Number of Pages: 66
Report Price:
PDF file by email: US$980
Site License: US$1,960
View Table of Contents...
Price
PDF Format $980.00
Site Licence pdf $1960.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.